Background : Patient with hypoxemic respiratory failure treated with NIV receive between NIV session oxygen therapy. Gaz exchange disorder with a decrease of the ratio between Partial Pressure of Arterial Oxygen (PaO2) and Inspired Fraction of Oxygen (FIO2) are noticed when NIV is stopped at the end of the session du to alveolar derecruitment Optiflow is a high flow oxygen delivery system used a heated humidifier and heated breathing circuit. In observational studies, Optiflow increase oxygenation of patients with hypoxemic respiratory failure. Oxygenation is better than under high-concentration mask and work of breathing is reduced. The aim of the study is to compare in acute hypoxemic respiratory failure, optiflow to oxygen therapy under high-concentration mask, on patients oxygenation between NIV sessions (measured as the difference between PaO2/FiO2 ratio at the beginning and at the end of the session), during the first two NIV sessions Study design : Prospective, randomized, controlled, multicentric, open clinical trial with two groups: * control group with conventional clinical management, oxygen therapy and sequential used of NIV * Optiflow group with high flow oxygen delivery system, conventional clinical management and sequential used of NIV for a period of 36 hours at least. Number of subjects: 100 (50 patients per group) patients admitted in intensive Care Unit for hypoxemic respiratory failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
95
Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least. High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%.
Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
Service de réanimation - CH de la côte basque
Bayonne, Aquitaine, France
Service de réanimation médicale - CHU de Bordeaux
Bordeaux, Aquitaine, France
Service de Réanimation Polyvalente - CH de Libourne
Libourne, Aquitaine, France
Service de Réanimation - CH de Perigueux
Périgueux, Aquitiane, France
Service de Réanimation Polyvalente - CHU de Toulouse
Toulouse, Midi-pyrenees, France
Service de Réanimation Polyvalente - CH d'Agen
Agen, France
Réanimation polyvalente - CH d'Albi
Albi, France
Réanimation Polyvalente - CH de Mont de Marsan
Mont-de-Marsan, France
Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.
Average of oxygenation differences measured as the delta between PaO2/FiO2 ratio at the end of the first NIV session and at the end of the first oxygen therapy session (according group of treatment) on the one hand and on the other hand the delta between PaO2/FiO2 ratio at the end of the second NIV session and at the end of the second oxygen thrapy session Five measurements of PaO2/FiO2 ratio are realized with arterial blood gases: * at the time of inclusion, * at the time of the end of first NIV session, * at the time of the end of first oxygen therapy session, or at the time of rescue NIV or at the time of réintubation * at the time of the end of second NIV session, * at the time of the end of second oxygen therapy session These five measurements are usually realised, and they are important to optimize patient management. The primary endpoint is based on these five measurements.
Time frame: 28 days
comfort score dyspnea beetween the two NIV sessions
The comfort score and dyspnea will be assessed between the two NIV sessions
Time frame: 28 days
Incidence of serious adverse events between the two NIV sessions
Time frame: 28 days
Respiratory rate between the two NIV sessions
Respiratory rate to assess work of breathing between the two NIV sessions
Time frame: 28 days
incidence of intubation during the NIV treatment of Acute respiratory distress syndrome (ARDS)
Time frame: 28 days
ICU mortality
Time frame: 28 days
28 days survival
Time frame: 28 days
Hospital mortality
Time frame: 28 days
ICU length of stay
Time frame: 28 days
duration of mechanical ventilation
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.